Hornet Therapeutics develops IDO-1 inhibitors to target Epstein-Barr Virus (EBV) driven pathologies, including post-transplantation lymphoproliferative disease (PTLD). The company's precision engineering of immune cell metabolism aims to provide a therapeutic option for patients facing high mortality rates due to EBV-related complications.
Funding
$8.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Epstein-Barr Virus (EBV) driven pathologies, such as post-transplantation lymphoproliferative disease (PTLD), present significant challenges, including organ loss in solid organ transplant recipients. Current management strategies for EBV-driven PTLD often require reduction in immunosuppression, which carries the risk of allo-graft rejection or organ loss. There are currently no therapeutic options available to treat reactivating or primary EBV infection.
Solution
Hornet Therapeutics is developing treatments to address Epstein-Barr Virus (EBV) driven pathologies by targeting IDO-1, a host enzyme hijacked by EBV. Their approach involves precision engineering of immune cell metabolism to modulate specific cellular states. The company's lead asset, HTX-201, is an IDO-1 inhibitor in-licensed from Kyowa Kirin. Hornet Therapeutics is initiating clinical trials to evaluate HTX-201 as a potential therapeutic intervention for preventing EBV-implicated diseases, including post-transplantation lymphoproliferative disease (PTLD).
Target Audience
The primary target audience includes patients with Epstein-Barr Virus (EBV) driven pathologies, particularly post-transplantation lymphoproliferative disease (PTLD), and clinicians seeking therapeutic options for these conditions.
Features
- Focus on single gene-level precision engineering of immune cell metabolism
- HTX-201: a lead asset IDO-1 inhibitor
- Targeting Epstein-Barr Virus (EBV) driven pathologies
- Developing treatments for post-transplantation lymphoproliferative disease (PTLD)